Search

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

EHA-HSH joint membership

Save money and time by becoming a joint member of EHA and the Hellenic Society of Haematology. We've joined forces with the Hellenic Society of Haematology (HSH) to offer a special joint membership deal.

Read more

SWG Educational Activities

Recruitment trialsRecruitment is underway for the following trials:

Trial on precision hematology: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2); ClinicalTrials.

Read more

Session information—May 15, 2025

Topic'Optimizing vaccination strategies for chemotherapy patients: Bridging gaps in preventive care. '

Speaker detailsVerena PetzerSince February 2025, Dr Verena Petzer has been a specialist in internal medicine for hematology and oncology at the Medical University of Innsbruck in Austria.

Read more

May 8 - International Thalassaemia Day

Every year on the 8th May, Thalassaemia International Federation commemorates the International Thalassaemia Day and organises activities for raising awareness about the genetic blood disorder of thalassaemia, on general topics regarding its prevention, management and cure.

Read more